Accretion and Dilution Is the First Question Asked About Any Deal
Whether an acquisition raises or lowers the buyer's earnings per share dominates deal conversations. It is a simple calculation, a weak measure of value, and it drives real decisions anyway.
The Test
An acquisition is described as accretive when the buyer's earnings per share increase after completing it, and dilutive when they fall. The calculation combines the two companies' earnings, adjusts for financing costs and expected synergies, and divides by the buyer's post deal share count.
It is usually the first question a board and the market ask, and it is answered on the announcement call.
Why Financing Drives the Answer
The result depends heavily on how the deal is paid for, which is the source of most confusion about it.
If a buyer uses cash sitting on the balance sheet earning very little, it gives up minimal income and gains the target's earnings, so the deal is likely accretive. If it borrows, it adds interest expense, and the deal is accretive when the target's earnings yield exceeds the after tax cost of the debt. If it issues shares, it adds to the share count, and the deal is accretive when the target's earnings yield exceeds the buyer's own.
A company trading at a high multiple buying one at a low multiple with stock will show accretion automatically. The arithmetic guarantees it regardless of whether the deal is wise.
The Central Weakness
That callout is the whole problem. Accretion follows mechanically from the relationship between multiples and the funding method. It does not indicate whether the price paid was reasonable, whether the businesses fit, or whether the projected synergies are achievable.
A highly rated acquirer can issue expensive shares to buy cheaper companies indefinitely and report rising earnings per share the entire time, while creating no value and possibly destroying it. Serial acquirers have used this dynamic for decades, and it works until growth slows and the multiple that made it possible compresses.
Conversely, a genuinely excellent acquisition of a fast growing business can be dilutive in year one because the target's current earnings are small relative to its price. Rejecting it on that basis would be an error.
What Actually Determines Value
The correct test is whether the return on the invested capital exceeds the cost of that capital, meaning whether the acquired cash flows plus realistic synergies, discounted properly, exceed the price paid.
That analysis is harder, depends on assumptions, and cannot be summarized in one word on an announcement call. Accretion persists because it is simple, verifiable within a year, and communicates easily, not because it is informative.
Synergies and Where They Hide
Deal models almost always include synergies, and cost synergies are more credible than revenue synergies. Eliminating duplicate functions and consolidating facilities produces savings that can be estimated and tracked. Revenue synergies, meaning selling more because the businesses are combined, are far harder to achieve and are frequently the first assumption to fail.
A useful discipline when reading a deal announcement is to recompute accretion excluding revenue synergies entirely and see whether the case still holds. Often it does not.
The Bottom Line
Accretion depends on multiples and funding structure rather than on whether a deal makes sense. Ask what return the purchase price earns against the cost of capital, and treat the accretion number as a communication device.